Artiva Biotherapeutics, Inc. (ARTV) Stock Score, Valuation & Financial Research

Artiva Biotherapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ARTV

Artiva Biotherapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 7.12. These figures are a research snapshot, not a buy or sell recommendation.

What Artiva Biotherapeutics, Inc. does

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Artiva Biotherapeutics is a clinical-stage biotechnology company that generates revenue primarily through license and development support agreements. The company focuses on the research, development, and commercialization of allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancers.

Products and services

  • The company's pipeline includes AlloNK, an allogeneic NK cell therapy candidate, and other CAR-NK product candidates currently in clinical development for various autoimmune and oncology indications.

Customer types

Clinical trial collaborators.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and product candidates. Source

Business relationships and partnerships

  • GC Cell — The company maintains an agreement with GC Cell, which granted Artiva an exclusive, royalty-bearing license in the Artiva Territory to research, develop, manufacture, and commercialize AB-205. Source

Business strengths to evaluate

  • Proprietary allogeneic NK cell therapy platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ARTV financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 7.12
Market capitalization:
348.1M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -90.82M
Free cash flow:
USD -79.34M
Cash:
USD 301.45M
Total debt:
USD 9.85M
EPS:
USD -3.31

What stands out

  • Free cash flow is USD -79.34M, negative for the stored period.
  • The balance sheet shows USD 301.45M of cash versus USD 9.85M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 291.61M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ARTV

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ARTV fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ARTV likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ARTV to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ARTV's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ARTV

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.